|
|
G3 |
|
Vaxjo ID |
384 |
|
Vaccine Adjuvant Name |
G3 |
|
Adjuvant VO ID |
VO_0005606
|
|
Description |
G3 is a novel particulate adjuvant formulated from cholesterol and Quil A components extracted from the tree Quillaja saponaria Molina. It is designed to enhance immune responses to vaccines. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
The immunomodulatory effect of a new particulate adjuvant, G3, alone or in combination with agonists to TLR2/1 or TLR5 was evaluated in cultures of equine PBMC. |
|
Structure |
G3 consists of a 20 nm particle formulation made from cholesterol and Quil A, but specific structural details are not provided. |
|
Function |
The immunomodulatory effect of a new particulate adjuvant, G3, alone or in combination with agonists to TLR2/1 or TLR5 was evaluated in cultures of equine PBMC. |
|
Safety |
The article indicates that G3 is well-tolerated and does not induce significant adverse effects, but specific safety data are not detailed. |
| References |
Hellman et al., 2018: Hellman S, Hjertner B, Morein B, Fossum C. The adjuvant G3 promotes a Th1 polarizing innate immune response in equine PBMC. Veterinary research. 2018; 49(1); 108. [PubMed: 30348190].
|
|
